The following related party transactions were undertaken during the year:
A director introduced amounts totalling £30,170 (2025: £147,812 ) and withdrew amounts totalling £209,732 (2025: £315,213). At the balance sheet date the amount payable was £64,536 (2025: £244,098 ).
Aura Infection Control Limited is a subsidiary of the company. During the year the company received loans from the subsidiary totalling £256,752 (2025: £342,118) and made repayments totalling £95,000 (2025: £25,000). At the balance sheet date the amount payable to Aura Infection Control Limited was £1,101,397 (2025: £939,645).
Dividends were paid to the directors in respect of their shareholdings £30,170 (2025: £20,925).
The aggregate remuneration paid to key management personnel for the year was £Nil (2025: £Nil).
No further transactions with related parties were undertaken such as are required to be disclosed in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.